Neurocysticercosis among patients with cerebral gliomas

Archives of Neurology

Volumn 54, Issue 9, 1997, Pages 1125-1128

  Del Brutto, Oscar H ^a,b   Castillo, Pablo R ^a   Mena, Ivän X ^a   Freire, Amado X ^a  

^a HOSPITAL LUIS VERNAZA   (Ecuador)

^b Air Center 3542   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLIOMA; GLIOSIS; HUMAN; MALE; NEUROCYSTICERCOSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030776811     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550210057013     Document Type: Article

References (30)

1. Schoenberg BS. Epidemiology of primary central nervous system neoplasms. In: Advances in Neurology. New York, NY: Raven Press; 1978;19:475-495.
2. Black PMcL Brain tumors. NEnglJMed. 1991:324:1471-1476.
3. Boeing H, Schlehofer B, Blettner M, Wahrendorf J. Dietary carcinogens and the risk for glioma and meningioma in Germany. Int J Cancer. 1993:53:561 -565.
4. Bondy ML, Kyritsis AP, Gu J, et al. Mutagen sensitivity and risk of gliomas: a case-control analysis. Cancer Res. 1996:56:1484-1486.
5. Zampieri P, Meneghini F, Grigoletto F, et al. Risk factors for cerebral glioma in adults: a case-control study in an Italian population. JNeurooncol. 1994;19:6167.
6. Giles GG, McNeil JJ, Donnan G, et al. Dietary factors and the risk of glioma in adults: results of a case-control study in Melbourne, Australia. Int J Cancer. 1994; 59:357-362.
7. Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors for the development of brain tumors. Cancer. 1992;69:2541-2547.
8. Walsh JW, Zimmer SG, Perdue ML Role of viruses in the induction of primary intracranial tumors. Neurosurgery. 1982;10:643-662.
9. Ryan P, Hurley SF, Johnson AM, et al. Tumours of the brain and presence of antibodies to Toxoplasma gondii. Int J Epidemiol. 1993:22:412-419.
10. Del Brutto OH, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis. 1988; 10:1075-1087.
11. Hautecoeur P, Gallois PH, Brucher JM, Ovelacq E, Dereux JF. Association d'une cysticercose cérébrale et d'un gliome multifocal: discussion des interactions. Rev Neurol (Paris). 1987;143:844-849.
12. Agapejev S, Alves A, Zanini MA, Ueda AK, Pereira EM. Oligodendroglioma cistico e positividade das reaçoes para cisticercose: relato de caso. Arq Neuropsiquiatr. 1992:50:234-238.
13. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol. 1993:3:255-268.
14. Del Brutto OH. Cysticercosis. In: Feldmann E, ed. Current Diagnosis in Neurology. St Louis, Mo: Mosby-Year Book Inc; 1994:125-129.
15. Sotelo J, Del Brutto OH, Roman GC. Cysticercosis. In: Remington JS, Swartz MM, eds. Current Clinical Topics in Infectious Diseases, 16. Cambridge, Mass: Blackwell Publishers; 1996:240-259.
16. Ridaura-SanzC. Host response in childhood neurocysticercosis. ChildsNervSyst 1987:3:206-207.
17. Soto-Hernandez JL, Ostrosky-Zeichner L, Tavera G, Gomez-Avina A. Neurocysticercosis and HIV infection: report of two cases and review. Surg Neurol. 1996; 45:57-61.
18. Badawi AF, Mostafa MH, Probert A, O'Connor PJ. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. EurJ Cancer Prev. 1995;4:45-49.
19. Hanes MA. Rbrosarcomas in two rats arising from hepatic cysts of Cysticercus fasciolaris. Vet Pathol. 1995:32:441-444.
20. Warren W, Biggs PJ, el Baz M, Ghonaim MA, Stratton MR, Venitt S. Mutations in the p53gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. 1995:16:11811189.
21. Escobar A. The pathology of neurocysticercosis. In: Palacios E, RodriguezCarbajal J, Taveras JM, eds. Cysticercosis of the Central Nervous System. Springfield, III: Charles C Thomas Publisher; 1983:27-54.
22. Silver SA, Erozan YS, Hruban RH. Cerebral Cysticercosis mimicking malignant glioma: a case report. Acta Cytol. 1996:40:351-357.
23. Flisser A. Taenia so/ium Cysticercosis: some mechanisms of parasite survival in immunocompetent hosts. Acta Leidensia. 1989;57:259-263.
24. White AC Jr, Tato P, Molinari JL. Host-parasite interactions in Taenia solium Cysticercosis. Infect Agents Dis. 1992;1:185-193.
25. Rolfs A, Muhlschlegel F, Jansen-Rosseck R, et al. Clinical and immunological follow-up study of patients with neurocysticercosis after treatment with praziquantel. Neurology. 1995:45:532-538.
26. Montera R, Flisser A, Madrazo I, Cuevas C, Ostrosky-Wegman P. Mutation at the HPRT locus in patients with neurocysticercosis treated with praziquantel. Mutât Res. 1994:305:181-188.
27. Schneider J, Hofman FM, Apuzzo MLJ, Hinton DR. Cytokines and immunoregulatory molecules in malignant glial neoplasms. J Neurosurg. 1992;77: 265-273.
28. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg. 1992;76: 799-804.
29. Moulignier A, Mikol J, Pialoux G, Eliaszewicz M, Thurel C, Thiebaut JB. Cerebral glial tumors and human immunodeficiency virus-1 infection: more than a coincidental association. Cancer. 1994;74:686-692.
30. Hishii M, Nitta T, Ishida H, et al. Human glioma-